Literature DB >> 10199840

Phospholamban deficiency does not compromise exercise capacity.

K H Desai1, E Schauble, W Luo, E Kranias, D Bernstein.   

Abstract

Deficiency of phospholamban (PLB) results in enhancement of basal murine cardiac function and an attenuated response to beta-adrenergic stimulation. To determine whether the absence of PLB also reduces the reserve capacity of the murine cardiovascular system to respond to stress, we evaluated the heart rate (HR), blood pressure, and metabolic responses of PLB-deficient (PLB-/-) mice to graded treadmill exercise (GTE). PLB-/- mice were hypertensive at rest (125 +/- 19 vs. 109 +/- 16 mmHg, P < 0.05) but had normal tachycardic and hypotensive responses to isoproterenol. The HR response to GTE was normal; however, the hypertension in PLB-/- mice normalized at peak exercise. Their exercise capacities, as measured by duration of exercise and peak oxygen consumption (VO2), were normal. The oxygen pulse (VO2/HR) curve was also normal in PLB-/- mice, suggesting an ability to appropriately increase stroke volume and oxygen extraction during GTE, despite an inability to increase beta-adrenergically stimulated cardiac contractility. Thus deficiency of PLB, although resulting in diminished beta-adrenergic inotropic reserve, does not compromise cardiac performance during exercise.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10199840     DOI: 10.1152/ajpheart.1999.276.4.H1172

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  10 in total

Review 1.  Targeting calcium cycling proteins in heart failure through gene transfer.

Authors:  Federica del Monte; Roger J Hajjar
Journal:  J Physiol       Date:  2003-01-01       Impact factor: 5.182

2.  Pleiotropy, homeostasis, and functional networks based on assays of cardiovascular traits in genetically randomized populations.

Authors:  Joseph H Nadeau; Lindsay C Burrage; Joe Restivo; Yoh-Han Pao; Gary Churchill; Brian D Hoit
Journal:  Genome Res       Date:  2003-09       Impact factor: 9.043

3.  Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy.

Authors:  K Freeman; I Lerman; E G Kranias; T Bohlmeyer; M R Bristow; R J Lefkowitz; G Iaccarino; W J Koch; L A Leinwand
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

4.  Local Ca2+ releases enable rapid heart rates in developing cardiomyocytes.

Authors:  Topi Korhonen; Risto Rapila; Veli-Pekka Ronkainen; Jussi T Koivumäki; Pasi Tavi
Journal:  J Physiol       Date:  2010-03-08       Impact factor: 5.182

5.  Optogenetic approach for functional assays of the cardiovascular system by light activation of the vascular smooth muscle.

Authors:  Yang Wu; Shan-Shan Li; Xin Jin; Ningren Cui; Shuang Zhang; Chun Jiang
Journal:  Vascul Pharmacol       Date:  2015-04-11       Impact factor: 5.773

6.  Long-term rescue of a familial hypertrophic cardiomyopathy caused by a mutation in the thin filament protein, tropomyosin, via modulation of a calcium cycling protein.

Authors:  Robert D Gaffin; James R Peña; Marco S L Alves; Fernando A L Dias; Shamim A K Chowdhury; Lynley S Heinrich; Paul H Goldspink; Evangelia G Kranias; David F Wieczorek; Beata M Wolska
Journal:  J Mol Cell Cardiol       Date:  2011-08-05       Impact factor: 5.000

7.  Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human.

Authors:  Kobra Haghighi; Fotis Kolokathis; Luke Pater; Roy A Lynch; Michio Asahi; Anthony O Gramolini; Guo-Chang Fan; Dimitris Tsiapras; Harvey S Hahn; Stamatis Adamopoulos; Stephen B Liggett; Gerald W Dorn; David H MacLennan; Dimitrios T Kremastinos; Evangelia G Kranias
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

8.  Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy.

Authors:  Qiujing Song; Albrecht G Schmidt; Harvey S Hahn; Andrew N Carr; Beate Frank; Luke Pater; Mike Gerst; Karen Young; Brian D Hoit; Bradley K McConnell; Kobra Haghighi; Christine E Seidman; Jonathan G Seidman; Gerald W Dorn; Evangelia G Kranias
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

9.  Validation of a Ramp Running Protocol for Determination of the True VO2max in Mice.

Authors:  Mohamed Ayachi; Romain Niel; Iman Momken; Véronique L Billat; Laurence Mille-Hamard
Journal:  Front Physiol       Date:  2016-08-29       Impact factor: 4.566

10.  Silk peptide treatment can improve the exercise performance of mice.

Authors:  Jisu Kim; Hyejung Hwang; Jonghoon Park; Hea-Yeon Yun; Heajung Suh; Kiwon Lim
Journal:  J Int Soc Sports Nutr       Date:  2014-07-01       Impact factor: 5.150

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.